Hi Guylène,

We have been struggling with this problem for some time and for the moment only the hospital and university affiliated family medicine teaching unit has developed a clear policy on drug rep visiting. I plan to ask the ethics committee of my hospital (a large university affiliated community hospital) to take a stand on this subject.

As for the etching unit, our policy is quite simple, NO VISITS allowed, only supervised and scheduled contact are allowed!

Drug reps are allowed contact with residents in training only during a « no free lunch » session, under the supervision of a senior doc., where they are asked to present their products and answer a few questions. They then leave and we have a discussion on the drug that was just presented and, most importantly, on sales techniques used by the drug rep during the encounter. 

There are a few policies available on the web:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411226/

http://www.amsascorecard.org/policy-docs/perelman-school-of-medicine-at-the-university-of-pennsylvania/4.UPenn-Hospital-Pharmacuetical-Activity.pdf

http://www.hopkinsmedicine.org/mediaII/Enews/articles/drugreps.html

https://www.ismp.org/newsletters/acutecare/articles/20080522.asp

http://www.pewtrusts.org/en/multimedia/data-visualizations/2013/task-force-recommendations-on-relationships-with-industry

Salutations et bonne chance!

Jean Levasseur

Le 2014-10-25 à 18:51, [log in to unmask] a écrit :

I recently was appointed as the medical director of a big hospital
I am searching for examples or strategies to tackle the influence of drug representatives in such a setting.
I know of the campaign in Australia but it seems more towards private practices.
Do anybody have examples in big hospitals?

Thanks

Envoyé de mon iPhone